Global Bladder Cancer Therapeutics Market 2017-2021

This market research study identifies Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, and Pfizer as the leading players in the global bladder cancer therapeutics market. A comprehensive analysis of this market is also presented by therapy (intravesical therapy, chemotherapy, and preservation therapy, and others) and by geography (the Americas, APAC, and EMEA).

Global bladder cancer therapeutics market forecasts

According to bladder cancer therapeutics industry insights, the global bladder cancer therapeutics market will grow at a CAGR of close to 5% during the forecast period. The availability of targeted therapy will be one of the major factors driving the growth prospects for the market until the end of 2021. The advancements in drug targeting techniques have enabled doctors to administer drugs directly into the bladder having tumors. This, in turn, will help in avoiding the side effects of these drugs on healthy cells. With a better understanding of tumor, immunology scientists can also now develop new drugs targeted at cancer cells. TECENTRIQ and OPDIVO are the PD-L1 inhibitors recently approved by the US FDA for the treatment of urothelial carcinoma.

One of the effective procedures for the diagnosis of bladder cancer, cystoscopy, involves the use of a long thin tube called cystoscope. This helps the urologist to extract a small piece of the abnormal tissue and send it to the pathologists for examination. With the emergence of effective diagnostic tools such as the flexible cystoscope, urologists will prefer cystoscopy since it can be easily performed in the outpatient department. This emergence of effective diagnostic tools will be one of the major trends that will gain traction in the bladder cancer therapeutics market during the next four years.

Competitive landscape and key vendors

The bladder cancer therapeutics market consists of a few vendors who concentrate on improving their profit margins through direct sales and through distributor channels. The competition among the players in this market space is mainly based on factors including emerging indications or applications and collaborations. To improve their market positions, the vendors are increasingly focusing on the development of new products and gaining approvals. To develop new products, a few vendors are also concentrating on partnering with other market players.  

Key vendors in this market are 

• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffman-La Roche
• Pfizer

Other prominent vendors in the market include Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.

Segmentation by therapy and analysis of the bladder cancer therapeutics market

• Intravesical therapy
• Chemotherapy
• Preservation therapy

Chemotherapy is mainly used for the treatment of invasive cancer and relieve bladder cancer symptoms by declining the rate at which cancer spreads. This market study estimates that the chemotherapy segment that includes neoadjuvant chemotherapy and adjuvant chemotherapy accounted for the major shares of the bladder cancer therapeutics market during 2016. This is mainly due to the increase in incidences of bladder cancer and the growing adoption of chemotherapy in the developing countries.

Segmentation by geography and analysis of the bladder cancer therapeutics market

• Americas
• APAC
• EMEA

Based on the bladder cancer therapeutics market growth analysis, the Americas will be the major revenue contributor to the market during 2016. Though the bladder cancer therapeutics market in the Americas will grow at a lesser rate than the other regions, this region will continue its market dominance throughout the predicted period due to factors such as the increasing focus of vendors to develop targeted therapies and the presence of major vendors such as Pfizer and Merck.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global bladder cancer therapeutics market?
• What are the key market trends impacting the growth of the global bladder cancer therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the global bladder cancer therapeutics market?
• What are the market opportunities and threats faced by the vendors in the global bladder cancer therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global bladder cancer therapeutics market?

Technavio also offers customization on reports based on specific client requirement.